Dear Editor:
We present a 58-year-old woman who experienced photopsia during and after her 24 th session of repetitive transcranial magnetic stimulation (rTMS) for the treatment of Major Depression. Symptoms persisted for a number of weeks and a posterior vitreous detachment was subsequently observed. We recommend close attention be paid to ophthalmic symptoms during the monitoring of rTMS side effects.
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Case
The patient is a 58 year old, single, single woman referred for rTMS for the third episode of recurrent major depressive disorder (current episode 4 years; previous episodes 17 years (duration 3 years) and 21 years (duration 1 year) ago)) that had not responded to four trials of antidepressants with one augmentation strategy and several psychotherapy programs. She had a history of chronic low back pain and right ankle pain resulting in a laminectomy and ankle reconstruction, hypothyroidism following a hemi-thyroidectomy for benign neoplasms, cholecystectomy for cholelithiasis and bilateral oophorectomy because of a high familial risk of malignancy. Her medications at the start of her rTMS sessions were pregabalin 75mg morning and 150mg at bedtime, minocycline 50mg daily; conjugated estrogens 0.625mg daily, rabeprazole 10mg daily, thyroxine 100mcg, 1 daily & 75mcg, 1 tab -5 days per week, metformin 1000 mg twice daily to assist weight reduction and agomelatine 50 mg at bedtime. These medications continued unchanged.
A pretreatment Depression Anxiety Stress Scale (DASS-21) [1] was severe for depression (score=12), extremely severe for anxiety (score=15) and moderate for stress (score=10) and a 17 item Hamilton Depression Rating Scale (HAM-D) score was 12. She began rTMS using high frequency stimulation with a Magventure device using a figure-of-eight coil applied to the left dorsolateral prefrontal cortex. rTMS treatments were given each weekday, each session consisting of 75 trains of 10 Hz over 4 seconds, 26 seconds between trains, at 110% of resting motor threshold (RMT). RMT was 50% of the machine output, determined as the lowest stimulus intensity required to produce a visual twitch in the right adductor pollicis brevis muscle in 3 of 6 test stimuli. Treatment was given at the F3 position, identified at each session using the 10/20 measurement method. The coil angle was 45° to the nasion.
When reviewed after 20 treatments, the patient felt more depressed, with irritability, fatigue and diffuse headaches and migraines. Her HAM-D score was 22, which may have related to concurrent significant financial stress. Immediately after session 23, she reported briefly seeing 'spots' with her left eye. During session 24, she experienced seeing a 'white out' with 'leaves falling' with her left eye for 30 seconds duration. She said that during this time, she could not see anything with her left eye.
She reported that on the morning after treatment 24, she woke up and noticed 
Discussion
rTMS is a well tolerated and very safe treatment [2] with serious adverse events, such as seizures, occurring rarely. [3] Only a few adverse ophthalmic events have previously been reported. Kung et al, [4] reported a 60 year old woman who developed PVD and a retinal tear during a course of rTMS for major depression. Taylor et al, [2] subsequently suggested this may have been due to incorrect coil placement during one treatment session. Karris and Capobianco, [5] reported a subconjunctival haemorrhage (SCH) during a course of rTMS for major depression and posttraumatic stress disorder in a 45 year old male with a history of deep venous thrombosis and a previous SCH, on warfarin. While the authors of both case reports did not conclude that rTMS had caused the ophthalmic events, the temporal relationship between them was noted.
This case had a strong temporal relationship between receiving rTMS and the development of photopsiae. These symptoms were attributed to vitreal syneresis, i.e., retinal stimulation at its anterior insertion due to presumed increased vitreal movement caused by stimulation of extra-ocular muscles. Photopsiae are a common presenting symptom, especially in myopic individuals; however, this patient is slightly hypermetropic. Photopsiae and floaters then persisted for several months before a PVD was diagnosed, making a link between rTMS and PVD hard to establish.
PVD is a degenerative process that increases in prevalence with age [6] , where the vitreous separates from the retina, either spontaneously or from trauma or rapid eye movement. [4] Increasing use of rTMS and any associated increase in reporting of ophthalmic symptoms will ultimately declare whether there is an association, but for the moment it remains unproven. In the meantime, the authors recommend that the very low risk of ophthalmic adverse events be explained to patients when consenting for rTMS and that monitoring for these symptoms becomes routine during a course of treatment.
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